Overview
- Xtant reported first‑quarter revenue of $20.9 million, with gross margin at 57.3% due to excess and obsolete inventory costs and a less favorable product mix.
- Full‑year 2026 revenue guidance rose to $101 million to $105 million as leaders pointed to contribution from new products and the core biologics portfolio.
- The company licensed Dillon Technologies’ HemoBlast Bellows, entering the roughly $2 billion market for surgical hemostatic agents that help stop bleeding in the operating room.
- Xtant closed the Companion Spine deal and received $10.7 million in proceeds, which it used to pay down debt and concentrate resources on higher‑margin biologics.
- Operational moves included the commercial launch of Trivium Shaped to streamline graft placement for surgeons and plans to expand the sales force to drive adoption and cross‑sell.